Equities

Procaps Group SA

Procaps Group SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.11
  • Today's Change0.539 / 94.23%
  • Shares traded17.35k
  • 1 Year change-56.41%
  • Beta0.0854
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Procaps Group SA is a Luxembourg-based healthcare and pharmaceutical company. The Company develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. It operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.

  • Revenue in USD (TTM)414.10m
  • Net income in USD52.20m
  • Incorporated2021
  • Employees5.50k
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
CASI Pharmaceuticals Inc22.06m-30.97m70.36m176.00--5.08--3.19-2.23-2.231.591.030.320.92652.03125,312.50-43.04-34.75-66.19-46.9154.3155.98-134.50-153.722.32--0.58---21.41--34.27--14.65--
Rockwell Medical Inc98.92m-1.24m71.10m237.00--2.4449.860.7188-0.0496-0.04963.230.90151.8014.4510.84417,371.30-2.25-46.29-3.34-65.3816.914.66-1.25-36.512.000.31940.2654--14.845.6954.82--76.21--
Journey Medical Corp57.77m-18.34m77.43m58.00--9.87--1.34-0.9276-0.92762.930.52710.8892.166.19996,051.80-28.22---76.21--57.32---31.74--1.03-13.650.6582--7.48--87.00------
I-Mab ADR-100.00bn-100.00bn77.57m220.00--0.33----------2.91-----------35.51---41.43-------509.54----0.00--111.86-13.6544.45---5.95--
Zhong Yuan Bio-Technology Holdings Ltd2.49m232.02k88.37m35.00391.37348.44--35.440.0128-0.01760.13950.01430.8583-1.613.2571,253.436.49--19.10--106.30--7.57--0.83092.530.8593---28.60---148.37------
Assertio Holdings Inc125.76m-68.49m92.07m53.00--0.7056--0.7321-0.7212-0.72121.321.370.38340.90522.342,372,887.00-20.88-21.51-30.33-32.0570.3188.68-54.46-62.101.57--0.2293---2.67-13.38-402.80---28.25--
Scilex Holding Co50.83m-171.53m105.77m113.00------2.08-1.40-1.400.4425-1.770.44015.221.55484,123.80-102.93------68.24---233.88--0.1853-3.72----22.90---614.67------
Procaps Group SA414.10m52.20m125.23m5.50k2.133.181.800.30240.52090.52094.160.34910.8541.873.3875,290.1810.77--19.01--55.04--12.61--0.9861--0.8829--0.0434--142.18------
Telomir Pharmaceuticals Inc0.00-22.96m132.36m1.00--299.40-----0.8145-0.81450.000.01490.00----0.00-721.99---1,752.70-------------2.060.00-------1,430.39------
Puma Biotechnology Inc243.57m23.24m142.35m185.006.112.004.090.58450.4750.4755.031.451.1517.915.831,316,589.0010.95-12.2118.85-20.5369.2978.789.54-11.791.403.610.5234--3.34-1.251,079,450.00--83.41--
Elutia Inc24.78m-60.29m152.07m54.00------6.14-2.10-1.840.8695-1.160.48132.828.52458,925.90-117.08-42.93-649.22-79.3442.4143.32-243.28-64.160.849-1.18-----49.69-8.71-25.39--12.74--
LifeVantage Corp196.01m4.13m164.83m217.0041.235.9321.710.84090.31920.319215.272.223.062.5071.64903,290.306.469.9510.1715.5579.2181.452.113.080.9923559.360.0026.95-6.20-2.4015.63-16.94-2.18--
Scpharmaceuticals Inc30.28m-80.12m173.10m135.00--5.64--5.72-1.91-1.910.74170.61370.2620.72684.52224,281.50-69.31-38.23-78.18-42.3169.72---264.60-1,360.166.89-8.420.6246-------48.79------
Data as of Nov 21 2024. Currency figures normalised to Procaps Group SA's reporting currency: US Dollar USD

Institutional shareholders

0.10%Per cent of shares held by top holders
HolderShares% Held
Lemanik Asset Management SAas of 30 Jun 202470.29k0.06%
Geode Capital Management LLCas of 30 Sep 202428.94k0.03%
Activest Wealth Management LLCas of 30 Sep 202410.00k0.01%
Pineridge Advisors LLCas of 30 Sep 2024250.000.00%
Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Sep 2024100.000.00%
Exome Asset Management LLCas of 30 Sep 20240.000.00%
SSgA Funds Management, Inc.as of 30 Sep 20240.000.00%
RBC Dominion Securities, Inc.as of 30 Sep 20240.000.00%
Credicorp Capital Asset Management SA AGFas of 30 Jun 20240.000.00%
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.